Neratinib resistance and cross-resistance to other HER2-targeted drugs due to increased activity of metabolism enzyme cytochrome P4503A4.

about

Resistance to HER2-targeted anti-cancer drugs is associated with immune evasion in cancer cells and their derived extracellular vesicles.Neratinib: First Global Approval.

P2860

Q47186997-BA4660CD-0FAC-468F-8290-1217A0AC72DC Q50201250-9FE24C34-288F-4EC0-8BE0-8D9E2B6E63AB

P2860

Neratinib resistance and cross-resistance to other HER2-targeted drugs due to increased activity of metabolism enzyme cytochrome P4503A4.

Item

http://www.wikidata.org/entity/Q38718320

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Neratinib resistance and cross ...... ism enzyme cytochrome P4503A4.

@en

type

Item

label

Neratinib resistance and cross ...... ism enzyme cytochrome P4503A4.

@en

prefLabel

Neratinib resistance and cross ...... ism enzyme cytochrome P4503A4.

@en

P1476

Neratinib resistance and cross ...... ism enzyme cytochrome P4503A4.

@en

P2093

Michelle C Lowry

http://www.w3.org/2001/XMLSchema#string

Susan Breslin

http://www.w3.org/2001/XMLSchema#string

P2860

FAM83A confers EGFR-TKI resistance in breast cancer cells and in mice

EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells

Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer.

Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas

Mechanisms of cancer drug resistance

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2).

Cytochrome P-450 3A4: regulation and role in drug metabolism.

PP2A inhibition overcomes acquired resistance to HER2 targeted therapy.

Docetaxel-resistance in prostate cancer: evaluating associated phenotypic changes and potential for resistance transfer via exosomes.

P2888

bjc.2016.445

P304

620-625

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BJC.2016.445

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

116

http://www.w3.org/2001/XMLSchema#string

P50

Lorraine O'Driscoll

P577

2017-02-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1083523368

http://www.w3.org/2001/XMLSchema#string

P698

28152547

http://www.w3.org/2001/XMLSchema#string

P932

5344284

http://www.w3.org/2001/XMLSchema#string

Neratinib resistance and cross-resistance to other HER2-targeted drugs due to increased activity of metabolism enzyme cytochrome P4503A4.

about

P2860

P2860

Neratinib resistance and cross-resistance to other HER2-targeted drugs due to increased activity of metabolism enzyme cytochrome P4503A4.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P50

P577

P6179

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P50

P577

P6179

P698

P932